Cargando…

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine

We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA (BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP MAbs) in treatment-refractory patients with chronic migraine (CM). We retrospectively reviewed the medical files of 19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argyriou, Andreas A., Dermitzakis, Emmanouil V., Xiromerisiou, Georgia, Vikelis, Michail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785576/ https://www.ncbi.nlm.nih.gov/pubmed/36548744 http://dx.doi.org/10.3390/toxins14120847

Ejemplares similares

Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up
por: Xiromerisiou, Georgia, et al.
Publicado: (2023)

Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
por: Vikelis, Michail, et al.
Publicado: (2018)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
por: Vikelis, Michail, et al.
Publicado: (2016)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
por: Charleston, Larry, et al.
Publicado: (2023)

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Argyriou, Andreas A., et al.
Publicado: (2023)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Vikelis, Michail, et al.
Publicado: (2023)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
por: Oterino, A., et al.
Publicado: (2011)

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
por: Scuteri, Damiana, et al.
Publicado: (2022)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Results of a Web-based survey of 2105 Greek migraine patients in 2020: demographics, clinical characteristics, burden and the effects of the COVID-19 pandemic on the course of migraine
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

Results of a Web-Based Survey on 2105 Greek Migraine Patients—Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients’ Reported Satisfaction
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience
por: Baldacci, Filippo, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
por: Lampl, Christian, et al.
Publicado: (2018)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study
por: Vikelis, Michail, et al.
Publicado: (2017)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lk7s3p6peukmcaocolb6b8p29r